10 Questions For Teva's BD Chief
This article was originally published in Scrip
Since joining Teva Pharmaceutical Co. Ltd. in 2013, Dr. Ivana Magovcevic-Liebisch, senior vice president and head of global business development, has been tasked with bringing innovation into the firm and leading partnerships and collaborations for the company's specialty pharma unit.
You may also be interested in...
Teva reported a drop in first quarter revenues that was smaller than expected on better sales from its specialty business. CEO Erez Vigodman claims the deal to acquire Allergan's generics business is on track to close in June and will transform Teva into an "even stronger company."
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.